Print

HVTN 120

NCT03122223

Trial Details:

I/II Ongoing
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, GlaxoSmithKline
ALVAC-HIV (vCP2438),gp120
?Healthy adults
RandD/trials/Lists/ClinicalTrialsList
9/30/2019
96ZM651 gp120 (clade C strain) linked to transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain); protein clade C TV1.C gp120 Env and clade C 1086.C gp120 Env with MF59 OR AS01
1 mL ALVAC-HIV injection in the left deltoid on Month 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Month 3 and 6. OR 1  mL ALVAC-HIV injection in the left deltoid on Month 0, 1, 3, and